Botanics & Health

January 1, 2017

Botanics and Health delivers swift, effective and long lasting pain relief using only the purest

organic materials available.

Botanics & Health

Problem worth solving

Today over $44 billion is spent annually in OTC topical analgesics by people desperate for pain relief. Despite this enormous amount of money spent looking for relief, many people suffer from chronic pain and addiction to pain killers.Botanics & Health

Our solution

B&H delivers safe, swift, effective and long lasting pain relief through an easily applied CBD topical lotion. The B&H lotion uses only the purest organics to provide pain relief in minutes that lasts for hours.

Botanics & Health

Target US consumer market

Botanics & Health

prospects248M

Market size:

GenX/Millenials

Silver Surfers 65+

$15.6B

US Market Size

05/02/2023

Regional Market Potential

05/02/2023

West Region CA NV Northwest Region WA OR

Northeast Region MA CT NY PA MD

Midwest Region MN South Region FL0

5

10

15

20

25

30

35

40

User Potential by Region (in millions)

Adults >21 Recreational Users Chronic Pain Sufferers

Competitors Why their solution is imperfect

Oral Over The Counter(OTC)

limited relief, maximum dosage, decreased effectiveness over time, side effects, does not break the Pain Cycle

Topical OTC limited relief, does not break the Pain Cycle

Hemp tincture or oillacks critical medicinal terpenes and secondary cannabinoids found in Cannabis oil.

Cannabis CBD tincture, oil, balmAll contain a minimum 20% THC. Able to be ingested, vaped or smoked - abused.

Competitive landscape

Botanics & Health

Botanics & Health How our solution is better

Topical LotionWorks in 5-10 minutes, no overdosing, no side effectsBreaks the Pain Cycle for good

Product EvolutionTru-Relief Pain Relief

Flagship Product 50mL CBD lotion• MS• Parkinson’s• Chronic lower back pain

• Migraines

• Shingles• Shoulder/Upper Back

Micro-encapsulated sublingual CBD lozenge • For swift, high potency efficacy• Available August 2017

Micro-encapsulated CBD Inhaler • For COPD, emphysema, chronic bronchitis and other pulmonary diseases• Available October 2017,

Date Milestone• December 23,

2016 Incorporation of IP Holding Company

• January 31, 2017 Sign California statewide delivery

• February 20, 2017

Sign New Distribution Colorado, Washington, Oregon and Arizona

• June 1, 2017 Launch New Branding

Key Dates

Botanics & Health

Team and key roles

Botanics & Health

Michael J SchultzCEO

Myk CaruanaDirector R&D

Pam CaruanaDirector Operations

Michael has been cited in the Congressional Record for his work, was cybersecurity and counterterrorism expert for the Senate Committee for Homeland Security, has started several and sold several high tech companies in the US, Brazil and Japan, earned the Juno Award for his work with the rock band Rush and is working with the DoD to treat TBI in the military.

Myk's successful experience developing unique strains and hybrids as well as different delivery and compounding is key to B&H's product success.Myk has previously held top secret clearance with the Air Force and has worked as an engineer for multiple high tech companies including Cisco.

Pam's experience in front office and manufacturing is key to running an efficient and profitable enterprise.Pam coordinates all operational aspects of B&H as well as acts as community outreach for B&H.

For further information please contact

Michael J. Schultz(702) 575-0349mjs@zenshadow.com

Botanics & Health

Demographic trends among older cannabis users in the United States, 2006–13Authors Benjamin H. Han et.al.Department of Medicine, Division of Geriatric Medicine and Palliative Care, New York University School of Medicine, New York, NY, USACenter for Drug Use and HIV Research, New York University College of Nursing, New York, NY, USAFirst published: 5 December 2016 Society for the Study of Addiction A large international survey on the medicinal use of cannabis conducted by the International Association for Cannabinoid Medicine in 31 countries found that 30.5% of the 953 participants surveyed were over the age of 50 [23]. The survey also found that the top five indications for cannabis use included chronic pain, anxiety, loss of appetite or weight loss, depression or sleeping disorder, all common conditions in older age.

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritisAuthors D.C. Hammell et.al.Department of Physiology, University of Kentucky College of Medicine, Lexington, KY, USA First published: 30 October 2015 European Journal of Pain Current arthritis treatments often have side-effects attributable to active compounds as well as route of administration. Cannabidiol (CBD) attenuates inflammation and pain without side-effects, but CBD is hydrophobic and has poor oral bioavailability. Topical drug application avoids gastrointestinal administration, first pass metabolism, providing more constant plasma levels.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?Authors: Javier Fernández-Ruiz et. al.Departamento de Bioquímica y Biología Molecular III, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, 28040-MadridCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28222-Majadahonda, Madrid, SpainInstituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28222-Majadahonda, Madrid, Spain

 Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, anxiolytic and antipsychotic agent, and is therefore a potential medicine for the treatment of neuroinflammation, epilepsy, oxidative injury, vomiting and nausea, anxiety and schizophrenia, respectively. The neuroprotective potential of CBD, based on the combination of its anti-inflammatory and anti-oxidant properties, is of particular interest and is presently under intense preclinical research in numerous neurodegenerative disorders.

Scientific Studies on CBD

Scientific Studies on CBD, cont.Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts

Authors: Natalya M. Kogan et. al.

Bone Research Laboratory, Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University

CBD leads to improvement in fracture healing and demonstrate the critical mechanical role of collagen crosslinking enzymes

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy

Authors: Sarah Jane Ward et. al.

Our data suggest that CBD is protective against PAC-induced neurotoxicity mediated in part by the 5-HT 1A receptor system. Furthermore, CBD

treatment was devoid of conditioned rewarding effects or cognitive impairment and did not attenuate PAC-induced inhibition of breast cancer cell viability.

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)

Source: GW Pharmaceuticals plc March 14, 2017 0:700 EDT

Study in the treatment of Dravet syndrome – a rare and severe form of epilepsy in children with no FDA-approved treatments

Primary endpoint achieved with high statistical significance (p=0.01) showing that Epidiolex treatment reduces convulsive seizures in children compared to placebo